Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;6(2):54-9.
doi: 10.2185/jrm.6.54. Epub 2011 Dec 17.

Collaboration between Hepatologists and Primary Care Physicians in Treating Patients with Chronic Hepatitis C

Junichi Tazawa  1 , Yoshinori Sakai  1 , Fumihiko Kusano  1 , Kazuyoshi Nagayama  1 , Hideomi Fujiwara  2
Affiliations

Collaboration between Hepatologists and Primary Care Physicians in Treating Patients with Chronic Hepatitis C

Junichi Tazawa et al. J Rural Med. 2011.

Abstract

Objective: The purpose of this study was to assess the treatment outcome in patients with chronic hepatitis C (CHC) using the current standard antiviral therapy when patient were treated in collaboration between hepatologists and primary care physicians (PCPs).

Patients and methods: One hundred and ten patients with CHC were treated with a combination therapy of peginterferon-alpha 2b and ribavirin. Among them, 25 patients were treated by a collaboration between hepatologists and PCPs (collaboration group), whereas 85 patients were treated with exclusively by hepatologists (noncollaboration group). The duration of the therapy was 48 weeks for 58 'difficult- to-treat' patients (genotype 1 with a high load of HCV-RNA; 1H patients) and 24 weeks for the remaining 52 patients (non-1H patients). In the collaboration group, antiviral therapy was initiated and adjusted, if needed, by hepatologists (visits every four weeks), whereas the weekly administration of peginterferon-alpha 2b was performed by PCPs. Clinical characteristics and the treatment outcome were compared between these two groups.

Results: The two groups had similar baseline characteristics. By intention to treat, the two groups showed similar rates of treatment-related serious adverse effects (0% vs. 1%, respectively) and dropout rates for adverse effects (8% vs. 13%, respectively). Sustained virologic response rates were also similar between the two groups, being 42% vs. 39% in the 58 1H patients (NS) and 62% vs. 64% in the 52 non-1H patients (NS), respectively.

Conclusions: Collaboration between hepatologists and PCPs may be a valid treatment alternative to treat patients with CHC using the current standard antiviral therapy.

Keywords: chronic hepatitis C; collaboration; peginterferon; primary care physician; ribavirin.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36: S121–S127. doi: 10.1002/hep.1840360716 - DOI - PubMed
    1. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355. - PubMed
    1. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 2006; 41: 17–27. doi: 10.1007/s00535-005-1740-7 - DOI - PubMed
    1. Iino S, Okita K, Omata M, et al. Clinical efficacy of PEG-Interferon α-2b and ribavirin combination therapy for 48 weeks in chronic hepatitis C patients with genotype 1 and high viral load—retrospective comparison with Interferon α-2b and ribavirin combination therapy for 24 weeks. Kan Tan Sui 2004; 49: 1099–1121(in Japanese).
    1. Inoue Y, Hiramatsu N, Oze T, et al. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepat 2010; 17: 336–344. doi: 10.1111/j.1365-2893.2009.01182.x - DOI - PubMed